Tobira Therapeutics (TBRA) has been under a strong bear grip, hence the stock is down -61% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 12.93% in the past 1 week. The stock has risen by 12.99% in the past week indicating that the buyers are active at lower levels, but the stock is down -60.6% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 26.46% and the 50-Day Moving Average is 51.75%. Tobira Therapeutics (NASDAQ:TBRA): stock turned positive on Friday. Though the stock opened at $4.38, the bulls momentum made the stock top out at $4.8 level for the day. The stock recorded a low of $4.1 and closed the trading day at $4.61, in the green by 5.98%. The total traded volume for the day was 1,429,881. The stock had closed at $4.35 in the previous days trading.
The company Insiders own 6.2% of Tobira Therapeutics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -17.77% . Institutional Investors own 59.54% of Tobira Therapeutics shares. During last six month period, the net percent change held by insiders has seen a change of -24.1%. Also, Cantor Fitzgerald initiates coverage on Tobira Therapeutics (NASDAQ:TBRA).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Cantor Fitzgerald announces the price target of $27 per share. The rating by the firm was issued on July 6, 2016.
Tobira Therapeutics, Inc., formerly Regado BioSciences, Inc., is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Companys lead product candidate, cenicriviroc (CVC), is an immunomodulator that can be used to treat a number of diseases, including non-alcoholic steatohepatitis (NASH), kidney fibrosis, HIV-1 and others. The Company is engaged in clinical studies for CVC, including the CENTAUR Study, an international, randomized Phase IIb study of CVC, and placebo in patients with NASH and liver fibrosis (NCT02217475). The Company has initiated ORION, a Phase IIa Study of Cenicriviroc in obese patients with fatty liver disease. It is also engaged in the Phase I pioglitazone safety combination study. NASH is a type of non-alcoholic fatty liver disease, or NAFLD. NAFLD is a liver disease and is associated with obesity and type-2 diabetes.